The study of identification of candidate genes integrates an international research network on ADHD genetics (“The ADHD Molecular Genetics Network”), coordinated by Prof. Stephen Faraone from Harvard University. In PRODAH, this research field is coordinated by Prof. Mara Helena Hutz, with collaboration of Prof. Tatiana Roman, both from Genetics Department of Federal University of Rio Grande do Sul (UFRGS). Ana Paula Miranda Guimarães e Júlia Pasqualini Genro, PhD students from Genetics and Molecular Biology Post-Graduation Program (UFRGS), Angélica Oliveira, Biological Sciences under degree student (UFRGS) and Gláucia Chiyoko Akutagava Martins, Biomedicine under degree student (Federal University of Health Sciences of Porto Alegre, UFCSPA) also develop projects related to this research field. Nowadays, many studies have clearly demonstrated a significant participation of genetic factors in ADHD etiology. Thus, it is not uncommon to find the disease also in parents and siblings of ADHD patients. The current effort concentrates mainly in the identification of the genes possibly involved, as well as the exact contribution of each one of these genes.
The farmacogenetic study is a project related to the above protocol and corresponds to one of the many possible ways genetics could influence clinical aspects of ADHD. Considering that there is a recent interest in evaluating the association between candidate genes and response to medication or adverse effects caused by medications commonly used for ADHD treatment, in this study we evaluate the relation of genes that can be involved in ADHD neurobiology or in drug action in CNS and the response to it. Initially developed in PRODAH by psychiatrists Cristian Zeni and Guilherme Polanczyk.
What would be the benefits if you join the study?
The child or adolescent with ADHD and biological parents will have access to a multidisciplinary evaluation through individual interviews with the objective of detecting and / or confirming the presence of ADHD. The patient will also have access to several neuropsychological tests that help to understand possible school problems he/she might be experiencing. In the case of a positive diagnosis, the patient’s attendance in the Program will be assured even if the family decides to quit the study during its course. Finally, your participation will help to acquire new knowledge that could benefit you, your family and other people who face the same problems.
What will be required from you if you join the study?
Besides the interviews and tests cited above, it will be necessary to collect a 5 ml blood sample from the patient and from one or both biological parents, to investigate, through DNA analysis, genes probably involved in ADHD.
Who is able to join the study (inclusion criteria)?
Children or adolescents with an ADHD diagnosis confirmed through the evaluation previously described who have one or both (preferably) biological parents available and willing to join the study.